BRPI0511026C1 - uso de um los neisserial, e, composição - Google Patents
uso de um los neisserial, e, composiçãoInfo
- Publication number
- BRPI0511026C1 BRPI0511026C1 BRPI0511026A BRPI0511026A BRPI0511026C1 BR PI0511026 C1 BRPI0511026 C1 BR PI0511026C1 BR PI0511026 A BRPI0511026 A BR PI0511026A BR PI0511026 A BRPI0511026 A BR PI0511026A BR PI0511026 C1 BRPI0511026 C1 BR PI0511026C1
- Authority
- BR
- Brazil
- Prior art keywords
- neisserial
- los
- tri
- outer core
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Amplifiers (AREA)
- Soft Magnetic Materials (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
uso de um los neisserial los neisserial, composição,e, método para produzir um los neisserial. a presente invenção refere-se a lipo-oligo-sacarídeos (los) neisseriais, que compreendem um núcleo externo de tri-sacarídeo, que apresenta aumentada ligação ao receptor dc-sign das células dendríticas, como resultado do que os los's neisseriais da invenção têm aumentada atividade imunoestimuladora. o núcleo externo de tri-sacarídeo dos los's neisseriais, combinados com uma porção de lipídeo a com reduzida toxicidade, é útil como um adjuvante em preparações de vacina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04076401 | 2004-05-11 | ||
| PCT/NL2005/000358 WO2005107798A1 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0511026A BRPI0511026A (pt) | 2007-11-27 |
| BRPI0511026B1 BRPI0511026B1 (pt) | 2019-01-08 |
| BRPI0511026B8 BRPI0511026B8 (pt) | 2020-01-21 |
| BRPI0511026C1 true BRPI0511026C1 (pt) | 2021-05-25 |
Family
ID=34928212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511026A BRPI0511026C1 (pt) | 2004-05-11 | 2005-05-11 | uso de um los neisserial, e, composição |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080138359A1 (pt) |
| EP (1) | EP1748791B1 (pt) |
| JP (1) | JP5174457B2 (pt) |
| KR (1) | KR101270838B1 (pt) |
| CN (1) | CN1997392B (pt) |
| AT (1) | ATE464066T1 (pt) |
| AU (1) | AU2005239963B2 (pt) |
| BR (1) | BRPI0511026C1 (pt) |
| CA (1) | CA2566409C (pt) |
| DE (1) | DE602005020608D1 (pt) |
| DK (1) | DK1748791T3 (pt) |
| ES (1) | ES2344114T3 (pt) |
| MX (1) | MXPA06013093A (pt) |
| NZ (1) | NZ551250A (pt) |
| PL (1) | PL1748791T3 (pt) |
| PT (1) | PT1748791E (pt) |
| SI (1) | SI1748791T1 (pt) |
| WO (1) | WO2005107798A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904581D0 (sv) * | 1999-12-15 | 1999-12-15 | A & Science Invest Ab | A novel helicobacter pylori-binding substance and use thereof |
| EP1962899B1 (en) | 2005-12-22 | 2011-08-17 | GlaxoSmithKline Biologicals S.A. | Pneumococcal polysaccharide conjugate vaccine |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2007113222A2 (en) | 2006-03-30 | 2007-10-11 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| CN101784282B (zh) | 2007-06-26 | 2015-07-08 | 葛兰素史密丝克莱恩生物有限公司 | 包含肺炎链球菌荚膜多糖缀合物的疫苗 |
| US8642046B2 (en) * | 2007-10-09 | 2014-02-04 | Tufts University | Cholera vaccines |
| NZ589812A (en) * | 2008-05-30 | 2012-08-31 | U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| WO2010130898A2 (fr) | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6 |
| WO2010130899A1 (fr) * | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Vaccin meningocoque a base de lipooligosaccharide (los) et de proteine de neisseria meningitidis |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2552480A1 (en) | 2010-03-26 | 2013-02-06 | GlaxoSmithKline Biologicals S.A. | Hiv vaccine |
| CN103228294A (zh) | 2010-09-27 | 2013-07-31 | 葛兰素史密斯克莱生物公司 | 疫苗 |
| KR20120068647A (ko) * | 2010-12-18 | 2012-06-27 | 아이진 주식회사 | 개선된 면역반응을 유도하는 백신 |
| WO2013006055A1 (en) | 2011-07-07 | 2013-01-10 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | A process for detergent-free production of outer membrane vesicles |
| GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
| US20170281744A1 (en) | 2014-12-10 | 2017-10-05 | Glaxosmithkline Biologicals Sa | Method of treatment |
| KR102002034B1 (ko) | 2015-07-09 | 2019-07-22 | 에스에프씨주식회사 | 고효율과 장수명을 갖는 유기 발광 소자 |
| EP3263695A1 (en) | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
| EP3533463A4 (en) * | 2016-10-31 | 2020-06-17 | Eyegene Inc. | IMMUNE REACTION REGULATING SUBSTANCE AND VACCINE COMPOSITION THEREFOR |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9101359A (nl) | 1991-08-07 | 1993-03-01 | Nederlanden Staat | Nieuw saccharide-peptide-conjugaat, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk saccharide-peptide-conjugaat omvat. |
| WO2000026384A1 (en) * | 1998-11-03 | 2000-05-11 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Lps with reduced toxicity from genetically modified gram negative bacteria |
| GB0103170D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| JP2005506322A (ja) * | 2001-08-31 | 2005-03-03 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種 |
| CA2493977A1 (en) * | 2002-08-02 | 2004-02-19 | Glaxosmithkline Biologicals Sa | Vaccine composition comprising lipooligosaccharide with reduced phase variability |
| US20090246224A1 (en) * | 2006-06-12 | 2009-10-01 | Nathalie Devos | Vaccine |
-
2005
- 2005-05-11 MX MXPA06013093A patent/MXPA06013093A/es active IP Right Grant
- 2005-05-11 SI SI200531025T patent/SI1748791T1/sl unknown
- 2005-05-11 KR KR1020067026018A patent/KR101270838B1/ko active IP Right Grant
- 2005-05-11 CN CN2005800181701A patent/CN1997392B/zh not_active Expired - Fee Related
- 2005-05-11 EP EP05745670A patent/EP1748791B1/en active Active
- 2005-05-11 WO PCT/NL2005/000358 patent/WO2005107798A1/en active Application Filing
- 2005-05-11 PL PL05745670T patent/PL1748791T3/pl unknown
- 2005-05-11 NZ NZ551250A patent/NZ551250A/en not_active IP Right Cessation
- 2005-05-11 JP JP2007513087A patent/JP5174457B2/ja not_active Expired - Fee Related
- 2005-05-11 ES ES05745670T patent/ES2344114T3/es active Active
- 2005-05-11 CA CA2566409A patent/CA2566409C/en not_active Expired - Fee Related
- 2005-05-11 AT AT05745670T patent/ATE464066T1/de active
- 2005-05-11 DK DK05745670.9T patent/DK1748791T3/da active
- 2005-05-11 PT PT05745670T patent/PT1748791E/pt unknown
- 2005-05-11 AU AU2005239963A patent/AU2005239963B2/en not_active Ceased
- 2005-05-11 BR BRPI0511026A patent/BRPI0511026C1/pt not_active IP Right Cessation
- 2005-05-11 US US11/596,319 patent/US20080138359A1/en not_active Abandoned
- 2005-05-11 DE DE602005020608T patent/DE602005020608D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ551250A (en) | 2010-03-26 |
| JP5174457B2 (ja) | 2013-04-03 |
| EP1748791A1 (en) | 2007-02-07 |
| JP2007537248A (ja) | 2007-12-20 |
| KR20070029742A (ko) | 2007-03-14 |
| ATE464066T1 (de) | 2010-04-15 |
| CA2566409C (en) | 2012-12-04 |
| DE602005020608D1 (de) | 2010-05-27 |
| SI1748791T1 (sl) | 2010-07-30 |
| CN1997392A (zh) | 2007-07-11 |
| AU2005239963B2 (en) | 2011-01-06 |
| BRPI0511026B1 (pt) | 2019-01-08 |
| AU2005239963A1 (en) | 2005-11-17 |
| MXPA06013093A (es) | 2007-08-08 |
| US20080138359A1 (en) | 2008-06-12 |
| CA2566409A1 (en) | 2005-11-17 |
| KR101270838B1 (ko) | 2013-07-04 |
| PT1748791E (pt) | 2010-07-15 |
| BRPI0511026B8 (pt) | 2020-01-21 |
| EP1748791B1 (en) | 2010-04-14 |
| DK1748791T3 (da) | 2010-06-28 |
| BRPI0511026A (pt) | 2007-11-27 |
| ES2344114T3 (es) | 2010-08-18 |
| CN1997392B (zh) | 2011-06-01 |
| WO2005107798A1 (en) | 2005-11-17 |
| PL1748791T3 (pl) | 2010-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511026A (pt) | uso de um los neisserial, e, composição | |
| DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
| WO2006012209A3 (en) | A new adjuvant composition | |
| BRPI0409133B8 (pt) | preparações farmacêuticas estavéis compreendendo metilnaltrexona | |
| HN2001000027A (es) | Derivados de purina | |
| UY28342A1 (es) | Nuevos compuestos | |
| MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
| WO2006081927A8 (de) | Guanidinogruppen-haltige siloxane und deren verwendung für kosmetische formulierungen | |
| BRPI0515316A (pt) | compostos de imidazoquinolina | |
| MY129263A (en) | Vaccine composition | |
| ATE246202T1 (de) | Gcsf konjugate | |
| NO20074908L (no) | Preparater inneholdende fettsyrer og/eller derivater derav og et lavtemperatur-stabiliseringsmiddel | |
| BR0309492A (pt) | Uso de pelo menos um álcool ramificado alcoxilado | |
| MXPA02011370A (es) | Iminoazinas substituidas. | |
| CU23759A3 (es) | Composiciones inmunogénicas | |
| AU2457100A (en) | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs | |
| TW200626132A (en) | Topical nepafenac formulations | |
| DK1469843T3 (da) | Komposition til farmaceutisk eller diætetisk anvendelse til at bekæmpe hårtab | |
| BR0314058A (pt) | Composições para cuidados pessoais a base de álcool ramificado | |
| DE60031886D1 (de) | Purinderivate | |
| BRPI0711425A8 (pt) | composições compreendendo tensoativos polimerizados de baixo dp e métodos de uso destas | |
| DK1420757T3 (da) | Kosmetiske mikroemulsioner indeholdende ectoin eller derivater | |
| BRPI0414732A (pt) | piridilacetilenos para uso como radiotraçadores e agentes de imageamento | |
| MY139010A (en) | 6-azo-5, 5'-dihydroxy -7,7'-disulfo-2-2'-dinaphthylamine derivatives | |
| CL2004000951A1 (es) | Compuestos de imidazopiridinas, su procedimiento de preparacion y su uso para preparar imidazopiridincetooxinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/01/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2505 DE 08/01/2019 QUANTO AO INVENTOR. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2670 DE 08-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |